Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May;65(634):e295-304.
doi: 10.3399/bjgp15X684817.

Impact of a printed decision aid on patients' intention to undergo prostate cancer screening: a multicentre, pragmatic randomised controlled trial in primary care

Viet-Thi Tran  1 , Elena Kisseleva-Romanova  2 , Laurent Rigal  2 , Hector Falcoff  3
Affiliations
Randomized Controlled Trial

Impact of a printed decision aid on patients' intention to undergo prostate cancer screening: a multicentre, pragmatic randomised controlled trial in primary care

Viet-Thi Tran et al. Br J Gen Pract. 2015 May.

Abstract

Background: Despite recommendations against systematic screening for prostate cancer, 70% of patients still request prostate-specific antigen testing.

Aim: To assess the impact of a decision aid on patients' intention to undergo prostate cancer screening.

Design and setting: Randomised controlled trial with two-arm parallel groups in 86 general practices in urban and rural areas in France.

Method: Males aged 50-75 years were randomised to receive either the decision aid (intervention group) or usual care (control group). The primary outcome was the proportion of patients' intending to undergo prostate cancer screening, assessed immediately after reading the decision aid. The reasons underlying their choice were elicited and the proportion of patients citing each reason to undergo, or not undergo, prostate cancer screening were compared between the two arms.

Results: A total of 1170 patients were randomised (588 in the intervention arm) from November 2012 to February 2013. The proportion of patients who intended to be tested for prostate cancer in the intervention arm (123 patients [20.9%]) was significantly reduced compared with the control arm (57 patients [9.8%]) (difference 11.1%, 95% confidence interval [CI] = 7.0 to 15.2, P<0.0001). In the intervention group, a lower proportion of individuals expressed that cancer screening would protect them from the disease, compared with the control group (P<0.0001), while a greater proportion of individuals stated that prostate cancer screening would not benefit their health (P<0.0001) and may involve procedures with harmful side effects (P = 0.0005).

Conclusion: The decision aid improved participants' informed decision making and reduced their intent to undergo prostate cancer screening.

Keywords: decision making; early detection of cancer; primary care; prostatic neoplasm; randomised controlled trial.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study flow chart.
See this image and copyright information in PMC

References

    1. Binder-Foucard F, Belot A, Delafosse P, et al. Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012. Étude à partir des Registres des Cancers du Réseau Francim — Partie 1: Tumeurs solides. Saint-Maurice: Institut de Veille Sanitaire; 2013. [Cancer national incidence and mortality in France between 1980 and 2012. Estimation based on the data of the French Cancer Registries Network — Part 1: Solid tumors]
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720. - PMC - PubMed
    1. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among US men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3):636–644. - PubMed
    1. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009;101(17):1216–1220. - PMC - PubMed

Publication types